Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

@inproceedings{Scatena2009VoreloxinAF,
  title={Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo},
  author={Caroline D. Scatena and Jeffrey L. Kumer and Jennifer P. Arbitrario and Anthony R. Howlett and Rachael Elizabeth Hawtin and Judith Ann Fox and Jeffrey A. Silverman},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2009}
}
Voreloxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, inducing site-selective DNA damage. Voreloxin is in clinical studies, as a single agent and in combination with cytarabine, for the treatment of acute myeloid leukemia (AML). The preclinical studies reported here were performed to investigate the activity of voreloxin alone and in combination with cytarabine, in support of the clinical program. Is single agent voreloxin active in… CONTINUE READING
Highly Cited
This paper has 35 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Therapies for acute myeloid leukemia: vosaroxin

OncoTargets and therapy • 2017
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Acute myeloid leukemia.

Hematology. American Society of Hematology. Education Program • 2004
View 5 Excerpts
Highly Influenced

Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2010
View 2 Excerpts

A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML)

F Ravandi, R Stuart, +10 authors C Berman
American Society of Clinical Oncology (ASCO) Annual Meeting • 2009
View 2 Excerpts

Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2007
View 1 Excerpt